EGFR and non-small cell lung carcinoma: In the OLCSG trial 1403, afatinib re-administration for sensitive EGFR-mutant NSCLC without T790M after resistance to 1G or 2G EGFR-TKIs yielded modest activity, with an ORR and DCR of 17% and 84%, respectively.